![](/images/general/no_picture/200_user.png)
Jay-ming Wang
Examiner (ID: 14318)
Most Active Art Unit | 3683 |
Art Unit(s) | 3683 |
Total Applications | 145 |
Issued Applications | 84 |
Pending Applications | 18 |
Abandoned Applications | 43 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16665100
[patent_doc_number] => 10934333
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-02
[patent_title] => Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
[patent_app_type] => utility
[patent_app_number] => 16/915745
[patent_app_country] => US
[patent_app_date] => 2020-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 41
[patent_no_of_words] => 98162
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915745
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/915745 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | Jun 28, 2020 | Issued |
Array
(
[id] => 16336536
[patent_doc_number] => 10787480
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-29
[patent_title] => Cytotoxic peptides and conjugates thereof
[patent_app_type] => utility
[patent_app_number] => 16/439204
[patent_app_country] => US
[patent_app_date] => 2019-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 41
[patent_no_of_words] => 62597
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 682
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16439204
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/439204 | Cytotoxic peptides and conjugates thereof | Jun 11, 2019 | Issued |
Array
(
[id] => 14774755
[patent_doc_number] => 20190262275
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => MULTI-DIMENSIONAL STRUCTURES FROM PEPTOID OLIGOMERS AND METHODS OF MAKING
[patent_app_type] => utility
[patent_app_number] => 16/406869
[patent_app_country] => US
[patent_app_date] => 2019-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8644
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16406869
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/406869 | MULTI-DIMENSIONAL STRUCTURES FROM PEPTOID OLIGOMERS AND METHODS OF MAKING | May 7, 2019 | Abandoned |
Array
(
[id] => 14715547
[patent_doc_number] => 20190248837
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-15
[patent_title] => Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
[patent_app_type] => utility
[patent_app_number] => 16/393651
[patent_app_country] => US
[patent_app_date] => 2019-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15667
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16393651
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/393651 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | Apr 23, 2019 | Issued |
Array
(
[id] => 15114563
[patent_doc_number] => 20190343914
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-14
[patent_title] => PEPTIDOMIMETIC MACROCYCLES
[patent_app_type] => utility
[patent_app_number] => 16/223473
[patent_app_country] => US
[patent_app_date] => 2018-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41231
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16223473
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/223473 | Peptidomimetic macrocycles | Dec 17, 2018 | Issued |
Array
(
[id] => 14158713
[patent_doc_number] => 20190106459
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-11
[patent_title] => COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 16/216773
[patent_app_country] => US
[patent_app_date] => 2018-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17739
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16216773
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/216773 | Compounds, linker-drugs and ligand-drug conjugates | Dec 10, 2018 | Issued |
Array
(
[id] => 15193869
[patent_doc_number] => 10494413
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-12-03
[patent_title] => Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
[patent_app_type] => utility
[patent_app_number] => 16/212178
[patent_app_country] => US
[patent_app_date] => 2018-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 41
[patent_no_of_words] => 98392
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16212178
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/212178 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | Dec 5, 2018 | Issued |
Array
(
[id] => 14273721
[patent_doc_number] => 20190134145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-09
[patent_title] => METHOD FOR TREATING COGNITIVE DYSFUNCTION
[patent_app_type] => utility
[patent_app_number] => 16/189833
[patent_app_country] => US
[patent_app_date] => 2018-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5902
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16189833
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/189833 | METHOD FOR TREATING COGNITIVE DYSFUNCTION | Nov 12, 2018 | Abandoned |
Array
(
[id] => 16288899
[patent_doc_number] => 10765722
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-08
[patent_title] => Angiotensin II alone or in combination for the treatment of hypotension
[patent_app_type] => utility
[patent_app_number] => 16/135608
[patent_app_country] => US
[patent_app_date] => 2018-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 10320
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16135608
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/135608 | Angiotensin II alone or in combination for the treatment of hypotension | Sep 18, 2018 | Issued |
Array
(
[id] => 14185231
[patent_doc_number] => 20190112320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-18
[patent_title] => METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/129008
[patent_app_country] => US
[patent_app_date] => 2018-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30611
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129008
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/129008 | Methods of preparing cytotoxic benzodiazepine derivatives | Sep 11, 2018 | Issued |
Array
(
[id] => 13729711
[patent_doc_number] => 20180369323
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-27
[patent_title] => MODULATION OF HEPATITIS B VIRUS CCCDNA TRANSCRIPTION
[patent_app_type] => utility
[patent_app_number] => 16/115298
[patent_app_country] => US
[patent_app_date] => 2018-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15827
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16115298
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/115298 | MODULATION OF HEPATITIS B VIRUS CCCDNA TRANSCRIPTION | Aug 27, 2018 | Abandoned |
Array
(
[id] => 13622063
[patent_doc_number] => 20180362583
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-20
[patent_title] => INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 16/113869
[patent_app_country] => US
[patent_app_date] => 2018-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31494
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16113869
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/113869 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | Aug 26, 2018 | Abandoned |
Array
(
[id] => 13622075
[patent_doc_number] => 20180362589
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-20
[patent_title] => ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/111027
[patent_app_country] => US
[patent_app_date] => 2018-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 81946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 114
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111027
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/111027 | Anthelmintic depsipeptide compounds | Aug 22, 2018 | Issued |
Array
(
[id] => 13536601
[patent_doc_number] => 20180319844
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-08
[patent_title] => CYCLIC PEPTIDE BINDER AGAINST ONCOGENIC K-RAS
[patent_app_type] => utility
[patent_app_number] => 16/031840
[patent_app_country] => US
[patent_app_date] => 2018-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16031840
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/031840 | Cyclic peptide binder against oncogenic K-Ras | Jul 9, 2018 | Issued |
Array
(
[id] => 13413191
[patent_doc_number] => 20180258138
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-13
[patent_title] => Biologically Cleavable Tetrapeptide Linking Agents
[patent_app_type] => utility
[patent_app_number] => 15/990415
[patent_app_country] => US
[patent_app_date] => 2018-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14430
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15990415
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/990415 | Biologically Cleavable Tetrapeptide Linking Agents | May 24, 2018 | Abandoned |
Array
(
[id] => 13576921
[patent_doc_number] => 20180340009
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-29
[patent_title] => PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
[patent_app_type] => utility
[patent_app_number] => 15/982700
[patent_app_country] => US
[patent_app_date] => 2018-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37299
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15982700
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/982700 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | May 16, 2018 | Abandoned |
Array
(
[id] => 16184454
[patent_doc_number] => 10717758
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-21
[patent_title] => D-amino acid compounds for liver disease
[patent_app_type] => utility
[patent_app_number] => 15/981813
[patent_app_country] => US
[patent_app_date] => 2018-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42169
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15981813
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/981813 | D-amino acid compounds for liver disease | May 15, 2018 | Issued |
Array
(
[id] => 13386401
[patent_doc_number] => 20180244742
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-30
[patent_title] => Double-Acylated GLP-1 Derivatives
[patent_app_type] => utility
[patent_app_number] => 15/966642
[patent_app_country] => US
[patent_app_date] => 2018-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35947
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15966642
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/966642 | Double-acylated GLP-1 derivatives | Apr 29, 2018 | Issued |
Array
(
[id] => 13386351
[patent_doc_number] => 20180244717
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-30
[patent_title] => CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/961531
[patent_app_country] => US
[patent_app_date] => 2018-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62302
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 527
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15961531
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/961531 | Cytotoxic peptides and conjugates thereof | Apr 23, 2018 | Issued |
Array
(
[id] => 13368995
[patent_doc_number] => 20180236038
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-23
[patent_title] => Liraglutide in cardiovascular conditions
[patent_app_type] => utility
[patent_app_number] => 15/956445
[patent_app_country] => US
[patent_app_date] => 2018-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15157
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15956445
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/956445 | Liraglutide in cardiovascular conditions | Apr 17, 2018 | Abandoned |